COMMUNIQUÉS West-GlobeNewswire

Counterpart Health Expands Leadership to Accelerate Enterprise Partnerships and Regional Adoption of AI-Powered Platform Counterpart Assistant
06/10/2025
New VP Blaine Lindsey to Drive National Enterprise Growth; Gulf Region President Shannon Jacobs to Scale Operations in High-Need Markets SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“ [...]
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
06/10/2025
Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « [...]
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
06/10/2025
Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/10/2025
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de Pharmakon Advisors et fait un point sur ses activités
06/10/2025
Le nouvel accord de prêt diffère le remboursement de la dette du premier trimestre 2026 au quatrième trimestre 2030, à un taux d’intérêt inférieur au précédent, et offre la possibilité d’obtenir davantage de financement [...]
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
06/10/2025
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business development Company adjusts 2025 financial guidance and provides key [...]
Pharming Group provides update on previously announced G&A expense reduction plan
06/10/2025
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company [...]
BPGbio Appoints Veteran Clinical and Commercial Leader Dr. Brian Berman as Interim Chief Medical Officer
06/10/2025
Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs Dr. Berman is a renowned scientist and clinical leader with a passion and track record in [...]
PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit
06/10/2025
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All amounts expressed in Canadian dollars unless otherwise noted TORONTO and RIONEGRO, Colombia, Oct. 06, 2025 (GLOBE [...]
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
06/10/2025
Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue [...]
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
06/10/2025
Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue [...]
Valitor Announces Upcoming Presentation at the Eyecelerator Conference Hosted in Conjunction with the American Academy of Ophthalmology (AAO) 2025 Annual Meeting
06/10/2025
Preclinical tolerability and retinal distribution data further support a 6-month dosing interval to treat wet AMD BERKELEY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new [...]
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
06/10/2025
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom’s leadership [...]
Hipp Health Raises $6.2 Million in Seed Funding
06/10/2025
Company Will Utilize Funds for Product Expansion, AI Investments, and Team Growth SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Hipp Health , an AI-native platform that streamlines administrative work, clinical [...]
Inspire Medical Systems, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025
06/10/2025
MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire’s [...]
Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL, the Native Asset of Solana Blockchain
06/10/2025
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued acquisition of Solana (“SOL”) tokens as part of its digital asset treasury [...]
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
06/10/2025
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere on the body for any [...]
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
06/10/2025
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
06/10/2025
- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., [...]

Pages